Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells

Recent evidence suggests that glutamate signaling plays an important role in cancer. Riluzole is a glutamate release inhibitor and FDA-approved drug for the treatment of amyotrophic lateral sclerosis. It has been investigated as an inhibitor of cancer cell growth and tumorigenesis with the intention...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolfi, Sonia C, Medina, Daniel J, Kareddula, Aparna, Paratala, Bhavna, Rose, Ashley, Dhami, Jatinder, Chen, Suzie, Ganesan, Shridar, Mackay, Gillian, Vazquez, Alexei, Hirshfield, Kim M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546507/
https://www.ncbi.nlm.nih.gov/pubmed/28591718
http://dx.doi.org/10.18632/oncotarget.17961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546507/
https://www.ncbi.nlm.nih.gov/pubmed/28591718
http://dx.doi.org/10.18632/oncotarget.17961

Ejemplares similares